Finding accredited CPD
This educational review outlines the burden of status epilepticus on the Australian patient population and summarises the rescue treatment options currently used in clinical practice in light of the August 2024 listing of ZYAMIS (intrabuccal midazolam formulation) on the Pharmaceutical Benefits Scheme for the treatment of generalised convulsive status epilepticus in patients over 1 year of age. It also includes guiding commentary from Professor Terence O'Brien, Chair of Medicine (Neurology) and Head of the School of Translational Medicine at Monash University. He also serves as Program Director of Alfred Brain and Deputy Director of Research at Alfred Health.
This educational review outlines the burden of status epilepticus on the Australian patient population and summarises the rescue treatment options currently used in clinical practice in light of the August 2024 listing of ZYAMIS (intrabuccal midazolam formulation) on the Pharmaceutical Benefits Scheme for the treatment of generalised convulsive status epilepticus in patients over 1 year of age.
This activity is accepted by CPD Home as Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide.
Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.
You have to log in to see the content of this module.
Provided by
Accepted by
*Medical Board of Australia’s (MBA)’s revised Registration Standard: Continuing professional development (the Standard)
